Viglimet Tablet (Vildagliptin 50mg + Metformin HCI 500mg) is used to Treat Type 2 Diabetes Mellitus when vildagliptin or metformin alone, along with diet and exercise, are ineffective in controlling blood sugar.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Viglimet 50/500mg Tablet is a combination of Vildagliptin (DPP-4 inhibitor) and Metformin (Biguanides), used to treat type 2 diabetes mellitus. Type 2 diabetes develops when the body does not produce enough insulin or when insulin does not work effectively. Galvus Met helps control blood sugar levels by increasing insulin production and decreasing glucagon release. It is not a substitute for insulin and should not be used to treat type 1 diabetes or diabetic ketoacidosis.
To ensure its effectiveness, Viglimet 50/500mg Tablet should be taken with food and at the same time each day. Your doctor will determine the appropriate dose based on your condition, and it may need to be adjusted over time. The most common side effect is hypoglycemia, characterized by symptoms like dizziness, sweating, palpitations, and hunger. To prevent hypoglycemia, do not skip meals and carry a source of sugar with you.
It is important not to stop taking Viglimet 50/500mg Tablet abruptly, even if you feel better, as sudden discontinuation may lead to an increase in sugar levels and potential complications like eyesight loss, kidney problems, and nerve damage.
Viglimet 50/500mg Tablet should not be used in type 1 diabetes or severe kidney or liver disease. Inform your doctor if you have any heart disease or if you are planning to get pregnant or breastfeed.
Always follow your doctor's instructions and continue to monitor your blood sugar levels while on Viglimet 50/500mg Tablet to effectively manage your diabetes. Metformin is a medication belonging to the class of drugs called Biguanides. It works by reducing the production of glucose in the liver, decreasing the absorption of glucose from the intestines, and improving insulin sensitivity in the body's peripheral tissues. This results in improved glucose tolerance and lower levels of both fasting and post-meal blood glucose.
Vildagliptin, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It acts by blocking the action of DPP-4, an enzyme responsible for inactivating incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, vildagliptin prolongs the activity of these incretin hormones in response to food intake. This leads to increased insulin sensitivity, reduced glucagon secretion, and improved function of beta cells in the pancreas, which ultimately results in better glycemic control.
Together, the combination of metformin and vildagliptin helps control blood sugar levels in patients with type 2 diabetes by targeting different aspects of glucose metabolism and insulin regulation. This dual mechanism of action makes the combination effective in managing the condition and achieving better glucose control.
Consumption of alcohol is not recommended during treatment with Viglimet 50/500mg Tablet since it may increase the risk of lactic acidosis.
Avoid during pregnancy as there is little information about its safety during pregnancy. Consult the doctor if you are pregnant or think you may be pregnant or are planning to have a baby before starting Viglimet 50/500mg Tablet.
Avoid taking Viglimet 50/500mg Tablet if you are a breastfeeding mother as its components are known to pass into breastmilk. Consult the doctor before using medication during breastfeeding.
Do not drive or operate any machines if you experience dizziness after taking Viglimet 50/500mg Tablet.
Viglimet 50/500mg Tablet is not recommended in patients with severely reduced kidney function. Consult your doctor before taking Viglimet 50/500mg Tablet.
Viglimet 50/500mg Tablet is not recommended in patients with liver disease. Consult your doctor before taking Viglimet 50/500mg Tablet.
Viglimet 50/500mg Tablet works by the combined action of both components - metformin and vildagliptin. It decreases the amount of glucose absorbed from the intestine, lowering the amount of sugar created by the liver and facilitating the entry of sugar into the cells.
Viglimet 50/500mg Tablet is used for the treatment of type 2 diabetes mellitus when Vildagliptin or Metformin alone, along with diet and exercise are ineffective in controlling the blood sugar.
Metformin is a medication belonging to the class of drugs called Biguanides. It works by reducing the production of glucose in the liver, decreasing the absorption of glucose from the intestines, and improving insulin sensitivity in the body's peripheral tissues. This results in improved glucose tolerance and lower levels of both fasting and post-meal blood glucose.
Vildagliptin, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It acts by blocking the action of DPP-4, an enzyme responsible for inactivating incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, vildagliptin prolongs the activity of these incretin hormones in response to food intake. This leads to increased insulin sensitivity, reduced glucagon secretion, and improved function of beta cells in the pancreas, which ultimately results in better glycemic control.
Together, the combination of metformin and vildagliptin helps control blood sugar levels in patients with type 2 diabetes by targeting different aspects of glucose metabolism and insulin regulation. This dual mechanism of action makes the combination effective in managing the condition and achieving better glucose control.
For adults with type 2 diabetes, the recommended starting dose of the Combination of Vildagliptin & Metformin is either 50 mg vildagliptin and 500 mg metformin or 50 mg vildagliptin and 850 mg metformin, twice daily. This means taking one tablet in the morning and one in the evening. The maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin HCl.
If a patient is already taking vildagliptin and metformin separately and wants to switch to the combination tablet, they should make sure the combination tablet contains the same doses of each component.
For patients with hepatic impairment (liver problems) or high pre-treatment ALT or AST levels (liver enzyme levels), this combination is not recommended.
For children under the age of 18, this combination is not recommended.
In patients with renal impairment (kidney problems), this combination should not be used if their serum creatinine levels are above 1.5 mg/dL in males and 1.4 mg/dL in females.
To take this combination medications, follow the doctor's instructions:
Always follow your doctor's instructions and consult them if you have any questions or concerns about the medication or its dosage.
Before taking Viglimet 50/500mg Tablet, it is important to inform your doctor about all the medications you are currently taking, as some drugs may interact with this combination and affect its effectiveness or increase the risk of side effects.
The following medications should be disclosed to your doctor before starting Viglimet 50/500mg Tablet:
If you suspect an overdose of Viglimet 50/500mg Tablet, or if you accidentally take too much of the medication, seek immediate medical attention. Overdose symptoms may include low blood sugar levels (hypoglycemia), lactic acidosis (a serious condition with high levels of lactic acid in the blood), muscle pain, mild and transient burning or tickling sensation in the body, fever, and edema (swelling).
This combination is contraindicated in individuals with:
Additionally, it should be temporarily stopped in patients undergoing radiologic tests that involve the intravascular injection of iodinated contrast materials, as such products may cause abrupt changes in renal function.
Viglimet 50/500mg Tablet is not recommended for individuals with congestive heart failure or those who have acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Since there is no available research on the use of the components of this combination during pregnancy and lactation, it should not be given to nursing mothers as it is unknown if Vildagliptin and/or Metformin Hydrochloride are excreted in human milk.
It's essential to follow the advice of your healthcare provider and inform them about any medical conditions or medications you are taking before starting any new medication. Safety and effectiveness are paramount, especially during pregnancy and lactation.
Store at a cool and dry place, protected from direct sunlight, moisture, and heat. Keep it away from children and pets. Avoid using expired medicines. Discard unused medicine properly. Avoid flushing into a toilet or throwing it into the drain.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.